Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Express Scripts
McKinsey
Harvard Business School

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,657,310

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,657,310
Title:Expression vector
Abstract: Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former.
Inventor(s): Takahashi; Kenichi (Hyogo, JP), Kakimoto; Shinji (Hyogo, JP)
Assignee: JCR PHARMACEUTICALS CO., LTD. (Ashiya-Shi, Hyogo, JP)
Application Number:14/396,929
Patent Claims:1. An expression vector for expression of a protein, comprising a gene expression regulatory site (A), and a gene encoding the protein downstream thereof, an internal ribosome entry site further downstream thereof, a gene encoding a glutamine synthetase still further downstream thereof, and additionally a dihydrofolate reductase gene downstream of another gene expression regulatory site (B) in addition to the former, wherein the internal ribosome entry site is derived from the 5' untranslated region of mouse encephalomyocarditis virus, wherein the internal ribosome entry site is that in which the 2nd or 3rd start codon from the 5' end has been destroyed by introducing one or more mutations into the nucleotide sequence of a wild-type internal ribosome entry site, and wherein the internal ribosome entry site comprises the nucleotide sequence set forth as SEQ ID NO:4.

2. The expression vector according to claim 1, wherein the gene expression regulatory site (A) is an elongation factor 1 promoter, and the gene expression regulatory site (B) is an SV40 early promoter.

3. The expression vector according to claim 1, further comprising, either in the region between the gene encoding the protein and the internal ribosome entry site or in the region downstream of the gene encoding the glutamine synthetase, another internal ribosome entry site in addition to the former internal ribosome entry site, and a drug resistance gene downstream thereof.

4. The expression vector according to claim 1, wherein the expression vector, in addition to the gene expression regulatory site (A) and the gene expression regulatory site (B), further comprises another gene expression regulatory site (C) and a drug resistance gene downstream thereof.

5. The expression vector according to claim 3, wherein the drug resistance gene is a neomycin resistance gene.

6. The expression vector according to claim 1, wherein the gene encoding the protein is a human-derived gene.

7. The expression vector according to claim 6, wherein the human-derived gene is selected from the group consisting of the genes encoding lysosomal enzymes, tissue plasminogen activator (t-PA), blood coagulation factors, erythropoietin, interferon, thrombomodulin, thyroid stimulating hormone (TSH), follicle-stimulating hormone, granulocyte colony-stimulating factor (G-CSF), and antibodies.

8. The expression vector according to claim 6, wherein the human-derived gene is a gene encoding a lysosomal enzyme.

9. The expression vector according to claim 8, wherein the lysosomal enzyme is selected from the group consisting of .alpha.-galactosidase A, iduronate-2-sulfatase, glucocerebrosidase, galsulfase, .alpha.-L-iduronidase, and acid .alpha.-glucosidase.

10. The expression vector according to claim 6, wherein the human-derived gene is a gene encoding erythropoietin.

11. An isolated mammalian cell transformed with the expression vector according to claim 1.

12. The isolated mammalian cell according to claim 11, wherein the cell lacks the intrinsic dihydrofolate reductase gene.

13. The isolated mammalian cell according to claim 11, wherein the cell is a CHO cell.

14. A method for production of a transformed cell expressing a gene encoding the protein comprising the steps of: (a) introducing the expression vector according to claim 1 into an isolated mammalian cell, (b) subjecting the mammalian cell containing the introduced expression vector to a selective culture in the presence of an inhibitor of dihydrofolate reductase, and (c) subjecting the cells selected through the selective culture to a further selective culture in the presence of an inhibitor of glutamine synthetase.

15. A method for production of a transformed cell expressing a gene encoding the protein comprising the steps of: (a) introducing the expression vector according to claim 3 into an isolated mammalian cell, (b) subjecting the mammalian cell containing the introduced expression vector to a selective culture in the presence of an inhibitor of dihydrofolate reductase, and (c) subjecting the cells selected through the selective culture to a further selective culture in the presence of an inhibitor of glutamine synthetase, further comprising the step of subjecting the mammalian cell containing the introduced expression vector to a selective culture in the presence of a drug corresponding to the drug resistance gene.

16. The expression vector according to claim 4, wherein the drug resistance gene is a neomycin resistance gene.

Summary for Patent: ➤ Sign Up

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2012-102796Apr 27, 2012
PCT Information
PCT FiledApril 25, 2013PCT Application Number:PCT/JP2013/062251
PCT Publication Date:October 31, 2013PCT Publication Number:WO2013/161958

Details for Patent 9,657,310

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biomarin NAGLAZYME galsulfase INJECTABLE; INJECTION 125117 001 2005-05-31 ➤ Sign Up JCR PHARMACEUTICALS CO., LTD. (Ashiya-Shi, Hyogo, JP) 2032-04-27 RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Cantor Fitzgerald
QuintilesIMS
Covington
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.